Yan Xia
Director, Antibody Drug Conjugate Research Center Huadong Medicine Co.,Ltd
Seminars
Wednesday 14th October 2026
Advancing a Novel Target Against Gastrointestinal Cancer to Undergo ADC Development in a Currently Underserved Indication
2:30 pm
- Delving into novel ADC target FGFR2b, MUC17 and CDH17 to treat gastrointestinal cancer, an indication currently underserved by ADC therapies
- Exploring preclinical and clinical development of CDH17 ADC in colorectal cancer
- Complementing bispecific design and linker-payload DAR optimization for next generation bispecific ADCs
